25
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Calcium Phosphate Spacers for the Local Delivery of Sitafloxacin and Rifampin to Treat Orthopedic Infections: Efficacy and Proof of Concept in a Mouse Model of Single-Stage Revision of Device-Associated Osteomyelitis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Osteomyelitis is a chronic bone infection that is often treated with adjuvant antibiotic-impregnated poly(methyl methacrylate) (PMMA) cement spacers in multi-staged revisions. However, failure rates remain substantial due to recurrence of infection, which is attributed to the poor performance of the PMMA cement as a drug release device. Hence, the objective of this study was to design and evaluate a bioresorbable calcium phosphate scaffold (CaPS) for sustained antimicrobial drug release and investigate its efficacy in a murine model of femoral implant-associated osteomyelitis. Incorporating rifampin and sitafloxacin, which are effective against bacterial phenotypes responsible for bacterial persistence, into 3D-printed CaPS coated with poly(lactic co-glycolic) acid, achieved controlled release for up to two weeks. Implantation into the murine infection model resulted in decreased bacterial colonization rates at 3- and 10-weeks post-revision for the 3D printed CaPS in comparison to gentamicin-laden PMMA. Furthermore, a significant increase in bone formation was observed for 3D printed CaPS incorporated with rifampin at 3 and 10 weeks. The results of this study demonstrate that osteoconductive 3D printed CaPS incorporated with antimicrobials demonstrate more efficacious bacterial colonization outcomes and bone growth in a single-stage revision in comparison to gentamicin-laden PMMA requiring a two-stage revision.

          Related collections

          Most cited references74

          • Record: found
          • Abstract: not found
          • Article: not found

          Treatment of infections associated with surgical implants.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis.

            A meta-analysis was performed to summarize the impact of methicillin-resistance on mortality in Staphylococcus aureus bacteremia. A search of the MEDLINE database for studies published during the period of 1 January 1980 through 31 December 2000 and a bibliographic review identified English-language studies of S. aureus bacteremia. Studies were included if they contained the numbers of and mortality rates for patients with methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) bacteremia. Data were extracted on demographic characteristics of the patients, adjustment for severity and comorbid illness, source of bacteremia, and crude and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for in-hospital mortality. When the results were pooled with a random-effects model, a significant increase in mortality associated with MRSA bacteremia was evident (OR, 1.93; 95% CI, 1.54-2.42; P<.001); significant heterogeneity was present. We explored the reasons for heterogeneity by means of subgroup analyses. MRSA bacteremia is associated with significantly higher mortality rate than is MSSA bacteremia.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover.

              Several growth factors are expressed in distinct temporal and spatial patterns during fracture repair. Of these, vascular endothelial growth factor, VEGF, is of particular interest because of its ability to induce neovascularization (angiogenesis). To determine whether VEGF is required for bone repair, we inhibited VEGF activity during secondary bone healing via a cartilage intermediate (endochondral ossification) and during direct bone repair (intramembranous ossification) in a novel mouse model. Treatment of mice with a soluble, neutralizing VEGF receptor decreased angiogenesis, bone formation, and callus mineralization in femoral fractures. Inhibition of VEGF also dramatically inhibited healing of a tibial cortical bone defect, consistent with our discovery of a direct autocrine role for VEGF in osteoblast differentiation. In separate experiments, exogenous VEGF enhanced blood vessel formation, ossification, and new bone (callus) maturation in mouse femur fractures, and promoted bony bridging of a rabbit radius segmental gap defect. Our results at specific time points during the course of healing underscore the role of VEGF in endochondral vs. intramembranous ossification, as well as skeletal development vs. bone repair. The responses to exogenous VEGF observed in two distinct model systems and species indicate that a slow-release formulation of VEGF, applied locally at the site of bone damage, may prove to be an effective therapy to promote human bone repair.
                Bookmark

                Author and article information

                Journal
                Pharmaceutics
                Pharmaceutics
                pharmaceutics
                Pharmaceutics
                MDPI
                1999-4923
                22 February 2019
                February 2019
                : 11
                : 2
                : 94
                Affiliations
                [1 ]Department of Biomedical Engineering, University of Rochester, Rochester, NY 14642, USA; ialatawn@ 123456u.rochester.edu (I.M.E.-A.); Edward_Schwarz@ 123456URMC.Rochester.edu (E.M.S.); Hani_Awad@ 123456URMC.Rochester.edu (H.A.A.)
                [2 ]Center for Musculoskeletal Research, University of Rochester, Rochester, NY 14642, USA; Mark_Ninomiya@ 123456URMC.Rochester.edu (M.J.N.); Emma_Gira@ 123456URMC.Rochester.edu (E.K.K.); Karen_Bentley@ 123456URMC.Rochester.edu (K.L.d.M.B.); Stephen.Kates@ 123456vcuhealth.org (S.L.K.)
                [3 ]Department of Microbiology and Immunology, University of Rochester, Rochester, NY 14642, USA; Paul_Dunman@ 123456URMC.Rochester.edu
                [4 ]Department of Pathology & Laboratory Medicine, University of Rochester, Rochester, NY 14642, USA
                [5 ]Department of Orthopedics, University of Rochester Medical Center, Rochester, NY 14642, USA
                [6 ]Department of Orthopaedic Surgery, Virginia Commonwealth University School of Medicine, Richmond, VA 0153, USA
                Author notes
                [* ]Correspondence: rtrombet@ 123456ur.rochester.edu ; Tel.: +1-585-273-5268
                Author information
                https://orcid.org/0000-0003-0479-5595
                Article
                pharmaceutics-11-00094
                10.3390/pharmaceutics11020094
                6410209
                30813284
                ae43cf30-df12-4d04-933c-bc149bb83929
                © 2019 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 16 January 2019
                : 17 February 2019
                Categories
                Article

                osteomyelitis,staphylococcus aureus,sitafloxacin,rifampin,calcium phosphate,3d printing,drug delivery,1-stage revision,pmma

                Comments

                Comment on this article